A phase III trial of recombinant human growth hormone in pediatric patients with growth failure caused by chronic kidney disease

Hong Xu(Sichuan University), Haiping Yang(DigitalSpace (United States)), Jianjiang Zhang(First Affiliated Hospital of Zhengzhou University), Wenyan Huang, Ke Xu(Hubei University of Arts and Science), Yubing Wu, Chaoying Chen, Xiaoyan Fang, Cuihua Liu(National Institutes for Quantum Science and Technology), Xiaoshan Tang, Zhihong Lu, Fei Zhao(Zhejiang Chinese Medical University), Ping Wang(Xi'an Polytechnic University), Yufeng Li, Jing Chen(Guangdong Pharmaceutical University), Jingjing Wang(Heilongjiang Academy of Sciences), Xiuli Wang(Jilin University), Zhi Chen(Yangzhou University), Xiaorong Liu(Hunan University of Traditional Chinese Medicine), Mo Wang(École Supérieure des Sciences Économiques et Commerciales), Aihua Zhang(Model Animal Research Center), Zihua Yu(Fujian Medical University), Liwen Sun, Yaju Zhu, Huijie Xiao(Beijing Forestry University), Qian Shen, Xiaojing Nie(Xian Central Hospital), Jun Huang(Ningbo No. 2 Hospital), Guanghai Cao, Jianhua Mao(Children's Hospital of Zhejiang University), Qiuxia Chen, Miao Wang(Harbin Electric Corporation (China)), Juan Tu(Collaborative Innovation Center of Advanced Microstructures)
Endocrine Abstracts
May 7, 2022
Cited by 0


Related Papers